

Karim Aouam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/396668/publications.pdf>

Version: 2024-02-01

66
papers

615
citations

686830

13
h-index

752256

20
g-index

74
all docs

74
docs citations

74
times ranked

618
citing authors

#	ARTICLE	IF	CITATIONS
1	Beta-lactam hypersensitivity in children: Frequency and risk factors. British Journal of Clinical Pharmacology, 2023, 89, 150-157.	1.1	1
2	Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA vaccine: A case report and brief literature review. British Journal of Clinical Pharmacology, 2023, 89, 536-540.	1.1	5
3	Cefotaxime-induced drug reaction with eosinophilia and systemic symptom in a child with cross-reactivity to other cephalosporins and cosensitization to teicoplanin. British Journal of Clinical Pharmacology, 2023, 89, 544-550.	1.1	2
4	DRESS characteristics according to the causative medication. European Journal of Clinical Pharmacology, 2022, 78, 1503-1510.	0.8	7
5	Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients. Pharmacogenomics Journal, 2021, 21, 69-77.	0.9	6
6	Isoniazid Therapeutic Drug Monitoring in Tunisian Patients With Tuberculosis. Journal of Clinical Pharmacology, 2021, 61, 972-978.	1.0	0
7	Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients. Pharmacogenomics Journal, 2021, 21, 467-475.	0.9	3
8	Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. Pharmacogenomics Journal, 2021, 21, 551-558.	0.9	6
9	Circadian variation in intestine toxicity of Mycophenolate mofetil in rats: an experimental and histopathologic study. Biological Rhythm Research, 2020, 51, 408-420.	0.4	0
10	Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosis. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 503-512.	0.7	5
11	Dosing algorithm for Tacrolimus in Tunisian Kidney transplant patients: Effect of CYP 3A4*1B and CYP3A4*22 polymorphisms. Toxicology and Applied Pharmacology, 2020, 407, 115245.	1.3	6
12	Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicology and Applied Pharmacology, 2020, 396, 115000.	1.3	7
13	Celecoxib-induced bullous fixed drug eruption: An unusual presentation. British Journal of Clinical Pharmacology, 2019, 85, 2638-2639.	1.1	4
14	Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermatitis, 2019, 81, 336-340.	0.8	28
15	Piroxicam-induced fixed drug eruption: Cross-reactivity with meloxicam. Contact Dermatitis, 2019, 81, 24-26.	0.8	9
16	Exanthema following a spider bite mimicking baboon syndrome. Contact Dermatitis, 2019, 81, 309-311.	0.8	0
17	Drug Rash with Eosinophilia and Systemic Symptoms: Captopril, an Unusual Culprit Drug. Dermatitis, 2019, 30, 238-239.	0.8	2
18	Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen. Nephrologie Et Therapeutique, 2019, 15, 110-114.	0.2	5

#	ARTICLE	IF	CITATIONS
19	Association of non-immediate drug hypersensitivity with drug exposure: A case control analysis of spontaneous reports from a Tunisian pharmacovigilance database. <i>European Journal of Internal Medicine</i> , 2018, 53, 40-44.	1.0	2
20	Is <i>p</i> -phenylenediamine a marker of sulfasalazine allergy?. <i>Contact Dermatitis</i> , 2018, 78, 173-174.	0.8	3
21	Distribution of Genetic Polymorphisms of Genes Implicated in Thiopurine Drugs Metabolism. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 655-659.	1.0	6
22	Meglumine antimoniate-induced DRESS: original case with a positive skin test. <i>Acta Parasitologica</i> , 2018, 63, 845-847.	0.4	2
23	Glibenclamide-induced photodistributed lichenoid eruption: An unusual association. <i>Therapie</i> , 2018, 73, 429-431.	0.6	3
24	Codeine-induced acute generalized exanthematous pustulosis without <i>IL36RN</i> mutations. <i>Pharmacogenomics</i> , 2018, 19, 889-893.	0.6	6
25	Dosing-time dependent oxidative effects of an immunosuppressive drug <i>Mycofenolate Mofetil</i> on rat kidneys. <i>Biomedicine and Pharmacotherapy</i> , 2017, 87, 509-518.	2.5	5
26	Circadian variation in anticonvulsant activity of valproic acid in mice. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 25-30.	2.5	6
27	Therapeutic drug monitoring of caffeine in preterm infants: Could saliva be an alternative to serum?. <i>Therapie</i> , 2017, 72, 685-689.	0.6	6
28	The rest of the story of the patient described in the letter to the editors: <i>Hyersensitivity to amoxicillin after</i> (DRESS) to carbamazepine: a possible co-sensitization™. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 784-785.	1.1	6
29	Circadian variation of cytotoxicity and genotoxicity induced by an immunosuppressive agent <i>Mycofenolate Mofetil</i> in rats. <i>Chronobiology International</i> , 2016, 33, 1208-1221.	0.9	4
30	Circadian variation of isoniazid pharmacokinetics in mice. <i>Biomedicine and Pharmacotherapy</i> , 2016, 84, 1150-1155.	2.5	6
31	Colloidal silica-induced hypersensitivity: myth or reality. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 7-9.	1.0	5
32	Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 524-530.	1.0	4
33	Influence of combined <i>CYP3A4</i> and <i>CYP3A5</i> single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. <i>Pharmacogenomics</i> , 2015, 16, 2045-2054.	0.6	30
34	Circadian variation in murine hepatotoxicity to the antituberculosis agent <i>Isoniazide</i> . <i>Chronobiology International</i> , 2015, 32, 1201-1210.	0.9	10
35	Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine. <i>Biomedicine and Pharmacotherapy</i> , 2015, 71, 233-239.	2.5	9
36	Circadian time-dependent hepatic and renal toxicities to valproic acid in mice. <i>Biological Rhythm Research</i> , 2015, 46, 847-861.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Circadian variation in hepatic toxicity of the immunosuppressive agent "Mycophenolate Mofetil" in rats. <i>Biological Rhythm Research</i> , 2015, 46, 739-751.	0.4	1
38	Gastrointestinal toxicity of mycophenolate mofetil in rats: Effect of administration time. <i>Chronobiology International</i> , 2015, 32, 1373-1384.	0.9	3
39	Albendazole-induced associated acute hepatitis and bicytopenia. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 149-151.	1.5	18
40	Circadian variation of mycophenolate mofetil pharmacokinetics in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 58, 20-25.	1.9	16
41	Celecoxib induced bullous eruption confirmed by a patch test. <i>Clinical and Translational Allergy</i> , 2014, 4, P81.	1.4	1
42	Circadian haematotoxicity of the antiepileptic valproic acid in mice. <i>Journal of Applied Biomedicine</i> , 2014, 12, 31-38.	0.6	4
43	Chronotolerance study of the antiepileptic drug valproic acid in mice. <i>Journal of Circadian Rhythms</i> , 2014, 10, 3.	2.9	16
44	A patch test confirmed phenobarbital-induced fixed drug eruption in a child. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2014, 13, 214-7.	0.3	4
45	Limited Sampling Strategy of Mycophenolic Acid in Adult Kidney Transplant Recipients: Influence of the Post-Transplant Period and the Pharmacokinetic Profile. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 925-933.	1.0	13
46	Circadian variation of Valproic acid pharmacokinetics in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 468-473.	1.9	23
47	Circadian variation in haematological toxicity of the immunosuppressive agent "Mycophenolate Mofetil" in rats. <i>Journal of Applied Biomedicine</i> , 2013, 11, 71-78.	0.6	11
48	Captopril-Induced DRESS. <i>Dermatitis</i> , 2013, 24, 255-257.	0.8	7
49	Murine circadian time-dependent tolerance to the immunosuppressive agent mycophenolate mofetil (MMF). <i>Biological Rhythm Research</i> , 2013, 44, 493-501.	0.4	0
50	Fixed Drug Eruption: a Selective Reaction to Amoxicillin. <i>Therapie</i> , 2013, 68, 183-185.	0.6	6
51	Delayed Cross-Reactivity Between Cyclophosphamide and Chlorambucil. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 771-774.	1.0	1
52	Fixed Drug Eruption: Levofloxacin, Another Culprit Drug. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 775-777.	1.0	9
53	Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Probably Induced by Cefotaxime: a Report of Two Cases. <i>Clinical Medicine and Research</i> , 2012, 10, 32-35.	0.4	13
54	Anti-inflammatory and Analgesic Activities of Tunisian <i>Apium graveolens</i> L. Leaves Extracts in Rats. <i>Journal of Biologically Active Products From Nature</i> , 2012, 2, 225-231.	0.1	4

#	ARTICLE	IF	CITATIONS
55	Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 429-432.	1.0	27
56	Amoxicillin-Induced Hypersensitivity After DRESS To Carbamazepine. <i>World Allergy Organization Journal</i> , 2010, 3, 220-222.	1.6	7
57	Hypersensitivity to amoxicillin after drug rash with eosinophilia and systemic symptoms (DRESS) to carbamazepine and allopurinol: a possible co-sensitization. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 273-276.	1.1	29
58	Hypersensitivity Syndrome Induced by Anticonvulsants: Possible Cross-Reactivity Between Carbamazepine and Lamotrigine. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1488-1491.	1.0	27
59	Lichenoid Eruption Associated with Hydrochlorothiazide and Possible Cross Reactivity to Furosemide. <i>Therapie</i> , 2009, 64, 344-347.	0.6	11
60	Acute generalised exanthematous pustulosis (AGEP) after cefotaxime use. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620080343-bcr0620080343.	0.2	1
61	Carbamazepine-induced DRESS and HHV6 primary infection: The importance of skin tests. <i>Epilepsia</i> , 2008, 49, 1630-1633.	2.6	28
62	Acenocoumarol and vasculitis: a case report. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 113-114.	0.9	18
63	Circadian Time-Dependent Differences in Murine Tolerance to the Antihistaminic Agent Loratadine. <i>Chronobiology International</i> , 2005, 22, 499-514.	0.9	10
64	Preconditioning of salvaged myocardium in conscious rabbits with postinfarction dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H2763-H2769.	1.5	11
65	Inhibitors of swelling-activated chloride channels increase infarct size and apoptosis in rabbit myocardium. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 555-561.	1.0	11
66	Evidence for a Ceiling of Cardioprotection with a Nitric Oxide Donor-Induced Delayed Preconditioning in Rabbits. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 528-531.	1.3	14